Want to see IN:INDSWFTLAB full AI Analyst Report?
INDSWFTLAB Stock Chart & Stats
₹227.00
₹12.42(5.46%)
At close: 4:00 PM EDT
₹227.00
₹12.42(5.46%)
Day’s Range― - ―
52-Week Range₹87.00 - ₹389.35
Previous CloseN/A
Volume478.31K
Average Volume (3M)77.85K
Market Cap
₹31.92B
Enterprise Value₹3.97K
Total Cash (Recent Filing)₹4.42B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)54.6
Beta0.85
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.82
Shares Outstanding86,961,555
10 Day Avg. Volume64,632
30 Day Avg. Volume77,846
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lower LeverageThe sharp reduction in leverage strengthens financial resilience, lowers interest and refinancing pressure, and gives the company greater flexibility to fund operations. Continued monitoring is warranted because leverage changed materially across years.
Stronger Capital BaseSteady equity growth provides a more durable buffer against operating volatility and supports the company’s ability to maintain pharmaceutical manufacturing capacity. A stronger capital base can also improve resilience while the business works through weaker recent earnings.
API Manufacturing PlatformParticipation in the API and intermediate supply chain gives the company an established role supplying inputs to finished-dose manufacturers. Domestic and export exposure can support recurring industrial demand and diversify customer opportunities, subject to compliance and execution.
Bears Say
Persistent Cash BurnThree consecutive years of negative free cash flow indicate that reported profitability is not converting reliably into cash. This can constrain investment, working-capital funding, and debt reduction, increasing financial risk if weak cash generation persists.
Recent Revenue ContractionBack-to-back revenue declines weaken operating scale and reduce visibility into customer demand, capacity utilization, and product realizations. Sustained contraction could pressure margins and make it harder to absorb fixed manufacturing and compliance costs.
Volatile ProfitabilityLarge swings in profitability reduce confidence in earnings durability and complicate planning for investment and working capital. The latest decline in EBIT and gross profit suggests operating momentum has weakened beyond the top-line contraction.
Ind-Swift Laboratories Ltd. News
INDSWFTLAB FAQ
What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?
Ind-Swift Laboratories Ltd. lowest stock price was ₹87.00 and its highest was ₹389.35 in the past 12 months.
What is Ind-Swift Laboratories Ltd.’s market cap?
Ind-Swift Laboratories Ltd.’s market cap is ₹31.92B.
When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?
Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 66 days.
How were Ind-Swift Laboratories Ltd.’s earnings last quarter?
Ind-Swift Laboratories Ltd. released its earnings results on Aug 12, 2026. The company reported ₹2.843 earnings per share for the quarter.
Is Ind-Swift Laboratories Ltd. overvalued?
According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued.
Does Ind-Swift Laboratories Ltd. pay dividends?
Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here
What is Ind-Swift Laboratories Ltd.’s EPS estimate?
Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ind-Swift Laboratories Ltd. have?
Ind-Swift Laboratories Ltd. has 86,961,555 shares outstanding.
What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?
Ind-Swift Laboratories Ltd. reported an EPS of ₹2.843 in its last earnings report. Following the earnings report the stock price went up 5.308%.
Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:INDSWFTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
Lincoln Pharmaceuticals Ltd
―
Solara Active Pharma Sciences Ltd.
―
Venus Remedies Limited
―